Novanta (FRA:1GSN) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1GSN Novanta Inc FRA:1GSN
88 GF Score
Price €126.00
GF Value €134.65
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Novanta Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:1GSN
88GF Score
Novanta Inc FRA:1GSN
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novanta (FRA:1GSN) Overvalued in 2026?

Based on GuruFocus' analysis, Novanta stock appears to be undervalued. The current stock price of €126.00 is trading 6.4% below its estimated GF Value™ of €134.65. GuruFocus considers Novanta to be Fairly Valued.

Key valuation signals for FRA:1GSN:

  • Short Ratio:
  • GF Value™: €134.65 vs. price of €126.00 (6.4% below fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the FRA:1GSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novanta Business Description

Address 125 Middlesex Turnpike, Bedford, MA, USA, 01730
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
88GF Score

Get the complete analysis for FRA:1GSN

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€126.00
Price
€134.65
GF Value